These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 11156227

  • 1. Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level.
    Ando M, Minami H, Ando Y, Saka H, Sakai S, Yamamoto M, Sasaki Y, Shimokata K, Hasegawa Y.
    Clin Cancer Res; 2000 Dec; 6(12):4733-8. PubMed ID: 11156227
    [Abstract] [Full Text] [Related]

  • 2. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
    Okamoto H, Nagatomo A, Kunitoh H, Kunikane H, Watanabe K.
    Cancer Chemother Pharmacol; 1998 Dec; 42(4):307-12. PubMed ID: 9744776
    [Abstract] [Full Text] [Related]

  • 3. Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula.
    Nagao S, Fujiwara K, Imafuku N, Kagawa R, Kozuka Y, Oda T, Maehata K, Ishikawa H, Koike H, Aotani E, Kohno I.
    Gynecol Oncol; 2005 Nov; 99(2):327-33. PubMed ID: 16005943
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies.
    de Lemos ML, Hsieh T, Hamata L, Levin A, Swenerton K, Djurdjev O, Vu T, Hu F, Conklin J, Malfair Taylor SC.
    Gynecol Oncol; 2006 Dec; 103(3):1063-9. PubMed ID: 16875719
    [Abstract] [Full Text] [Related]

  • 5. Flat dosing of carboplatin is justified in adult patients with normal renal function.
    Ekhart C, de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH.
    Clin Cancer Res; 2006 Nov 01; 12(21):6502-8. PubMed ID: 17085665
    [Abstract] [Full Text] [Related]

  • 6. Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia.
    Herrington JD, Tran HT, Riggs MW.
    Cancer Chemother Pharmacol; 2006 Jan 01; 57(2):241-7. PubMed ID: 16133538
    [Abstract] [Full Text] [Related]

  • 7. Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer.
    Shimokata T, Ando Y, Yasuda Y, Hamada A, Kawada K, Saito H, Matsuo S, Kondo M, Imaizumi K, Hasegawa Y.
    Cancer Sci; 2010 Dec 01; 101(12):2601-5. PubMed ID: 20860621
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin.
    Holweger K, Lipp HP, Beijnen JH, Bokemeyer C, Hartmann JT.
    Cancer Chemother Pharmacol; 2011 Sep 01; 68(3):693-701. PubMed ID: 21136060
    [Abstract] [Full Text] [Related]

  • 9. Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing.
    Ando Y, Minami H, Saka H, Ando M, Sakai S, Shimokata K.
    Br J Cancer; 1997 Sep 01; 76(8):1067-71. PubMed ID: 9376268
    [Abstract] [Full Text] [Related]

  • 10. Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing.
    Donahue A, McCune JS, Faucette S, Gillenwater HH, Kowalski RJ, Socinski MA, Lindley C.
    Cancer Chemother Pharmacol; 2001 May 01; 47(5):373-9. PubMed ID: 11391850
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma.
    Niioka T, Uno T, Yasui-Furukori N, Takahata T, Shimizu M, Sugawara K, Tateishi T.
    Cancer Chemother Pharmacol; 2007 Apr 01; 59(5):575-80. PubMed ID: 16912889
    [Abstract] [Full Text] [Related]

  • 12. [Differences between the glomerular filtration rate estimated by the MDRD equation and the measurement of creatinine and urea clearance in unselected patients with terminal renal insufficiency].
    Caravaca F, Arrobas M, Luna E, Naranjo M, Pizarro JL, Sánchez-Casado E.
    Nefrologia; 2002 Apr 01; 22(5):432-7. PubMed ID: 12497744
    [Abstract] [Full Text] [Related]

  • 13. [Evaluation of expected AUC of carboplatin (CBDCA) predicted by Chatelut's formula in comparison with Calvert's].
    Nakamura T, Onishi Y, Kono T, Maeda T, Wada T, Hatae M.
    Gan To Kagaku Ryoho; 1997 Mar 01; 24(5):579-83. PubMed ID: 9087291
    [Abstract] [Full Text] [Related]

  • 14. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
    Glorieux P, Ortmanns P, Marien S, Degives R, Degraeve D, Potvin M, Grauwels D, Schallier D.
    Anticancer Res; 2001 Mar 01; 21(2B):1487-94. PubMed ID: 11396237
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
    Warren K, Gervais A, Aikin A, Egorin M, Balis FM.
    Cancer Chemother Pharmacol; 2004 Sep 01; 54(3):206-12. PubMed ID: 15156345
    [Abstract] [Full Text] [Related]

  • 16. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
    Ekhart C, Rodenhuis S, Schellens JH, Beijnen JH, Huitema AD.
    Cancer Chemother Pharmacol; 2009 Jun 01; 64(1):115-22. PubMed ID: 18989671
    [Abstract] [Full Text] [Related]

  • 17. A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients.
    Schmitt A, Gladieff L, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Serre-Debauvais F, Pinguet F, Floquet A, Billaud E, Le Guellec C, Penel N, Campone M, Largillier R, Capitain O, Fabbro M, Houede N, Medioni J, Bougnoux P, Lochon I, Chatelut E.
    Clin Cancer Res; 2009 May 15; 15(10):3633-9. PubMed ID: 19401344
    [Abstract] [Full Text] [Related]

  • 18. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods.
    Huitema AD, Mathôt RA, Tibben MM, Schellens JH, Rodenhuis S, Beijnen JH.
    Clin Pharmacol Ther; 2000 Jun 15; 67(6):621-30. PubMed ID: 10872644
    [Abstract] [Full Text] [Related]

  • 19. Dose individualization can minimize nephrotoxicity due to carboplatin therapy in patients with ovarian cancer.
    Donadio C, Lucchesi A, Ardini M, Cosio S, Fanucchi A, Gadducci A.
    Ther Drug Monit; 2009 Feb 15; 31(1):63-9. PubMed ID: 19077927
    [Abstract] [Full Text] [Related]

  • 20. [Usefulness of the formula for predicting creatinine clearance from serum cystatin C].
    Oyabu C, Hayashi N, Sugiyama D, Umezu M, Kinoshita S, Hayashi H, Kawano S, Kumagai S.
    Rinsho Byori; 2008 Dec 15; 56(12):1093-9. PubMed ID: 19175073
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.